Latest News
NAPWHA & AFAO oppose move to introduce mandatory HIV testing
The National Association of People with HIV (NAPWHA), Australia’s peak non-government organisation representing community-based groups of people with HIV (PLHIV), and AFAO, the peak national organisation for Australia’s community HIV response – strongly oppose moves by NSW Labor to introduce a Bill to enforce mandatory testing of individuals whose bodily fluids come into contact with emergency services personnel, such as police officers.
NAPWHA reports back from member’s AGM 2019
NAPWHA members and associates from all Australian States and Territories and New Zealand gathered for the annual general meeting in Sydney, on 26 October 2019, also co-jointly with AFAO members on 27 October 2019. The warmest of welcomes were extended to Sydney-based Bobby Goldsmith Foundation (BGF), Papua New Guinea’s Igat Hope Inc., and Estrela+ of Timor-Leste, which were admitted as associate members.
NAPWHA welcomes the new board
NAPWHA wishes to inform our organisational membership, partners and community/ies of the 2019 NAPWHA Board election results ahead of our Annual General Meeting in late-October.
NAPWHA congratulates Positive Life NSW on appointment of their new Chief Executive Officer
NAPWHA congratulates Positive Life NSW on their announcement of the appointment of Jane Costello as CEO, effective from Monday 11 November 2019.
NAPWHA joins call-to-action on HIV in PNG
NAPWHA has joined key stakeholders in the HIV response in urging donors, governments, communities and people living with HIV to redouble their efforts to address the HIV ‘crisis’ in Papua New Guinea (PNG). The Call to Action, Critical Concerns for HIV Treatment and...
Pharmaceutical Benefits Scheme to delist Stribild® and Eviplera® from 1 March 2020
NAPWHA wish to update our HIV community/ies and organisational members that from 1 March 2020 the Single Tablet Regimen (STR) HIV treatments Eviplera ® (tenofovir disoproxil fumarate, emtricitabine and rilpivirine) and Stribild ® (cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil fumarate) will no longer be available via the Australian Pharmaceutical Benefits Scheme (PBS).
